Algernon Pharmaceuticals (Algernon Pharmaceuticals) FCF Margin % : 0.00% (As of Nov. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Algernon Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Algernon Pharmaceuticals's Free Cash Flow for the three months ended in Nov. 2023 was $-0.04 Mil. Algernon Pharmaceuticals's Revenue for the three months ended in Nov. 2023 was $0.00 Mil. Therefore, Algernon Pharmaceuticals's FCF Margin % for the quarter that ended in Nov. 2023 was 0.00%.

As of today, Algernon Pharmaceuticals's current FCF Yield % is -68.63%.

The historical rank and industry rank for Algernon Pharmaceuticals's FCF Margin % or its related term are showing as below:

AGNPF's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -148.935
* Ranked among companies with meaningful FCF Margin % only.

Algernon Pharmaceuticals FCF Margin % Historical Data

The historical data trend for Algernon Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algernon Pharmaceuticals FCF Margin % Chart

Algernon Pharmaceuticals Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

FCF Margin %

Get a 7-Day Free Trial

Algernon Pharmaceuticals Quarterly Data
	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Algernon Pharmaceuticals's FCF Margin %

For the Biotechnology subindustry, Algernon Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Algernon Pharmaceuticals's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Algernon Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Algernon Pharmaceuticals's FCF Margin % falls into.

Algernon Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Algernon Pharmaceuticals's FCF Margin for the fiscal year that ended in Aug. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Aug. 2023 )	/	Revenue (A: Aug. 2023 )
	=	-1.939	/	0
	=	%

Algernon Pharmaceuticals's FCF Margin for the quarter that ended in Nov. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Nov. 2023 )	/	Revenue (Q: Nov. 2023 )
	=	-0.038	/	0
	=	%

Algernon Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of Algernon Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Algernon Pharmaceuticals (Algernon Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algernon Pharmaceuticals Inc (OTCPK:AGNPF) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

AGW0:Germany AGN:Canada

Address

601 West Broadway, Suite 400, Vancouver, BC, CAN, V5Z 4C2

Website

https://www.algernonpharmaceuticals.com

Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.